Skip to main content

Table 3 Multivariate associations with successful TNFi discontinuation with and without MBDA score as a predictor

From: Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment

  With MBDA Without MBDA
Predictor OR 95% CI P OR 95% CI P
anti-TNF monoclonal antibodya 2.41 1.58–3.67 < 0.0001 2.46 1.61–3.73 < 0.0001
Disease duration < 10 yrs. 2.15 1.42–3.26 < 0.0001 2.14 1.42–3.23 < 0.0001
MBDA score ≤ 44 2.00 1.10–3.64 0.023
  1. aReference category is receptor antagonist
  2. TNFi tumor necrosis factor-alpha inhibitors, MBDA multi-biomarker disease activity, OR Odds ratio. Hosmer and Lemeshow with MBDA χ2(5) = 1.57, P = 0.905, area under ROC curve = 0.66 (95% CI: 0.61–0.71, P < 0.0001); Hosmer and Lemeshow without MBDA χ2(2) = 0.00, P = 1.000, area under ROC curve = 0.65 (95% CI: 0.59–0.70, P < 0.0001)